Research Progress Related to Polymyalgia Rheumatica and Giant Cell Arteritis
Investigators at the National Institutes of Health (NIH) and at other research centers across the country, many supported by the NIH, are working to understand what causes polymyalgia rheumatica and giant cell arteritis and to develop new treatment strategies. Current research efforts include the following.
- More effective and safer therapies are being studied throughout the world. Several large clinical trials are currently underway to find steroid-sparing immunosuppressives that block inflammation caused by giant cell arteritis or polymyalgia rheumatica.
- Researchers are working to evaluate how long patients need to stay on medications for polymyalgia rheumatica and giant cell arteritis.
- By comparing the DNA of people with the disorders to healthy controls, investigators are searching for gene variants that may raise the risk of polymyalgia rheumatica and giant cell arteritis.
- Polymyalgia rheumatica and giant cell arteritis can be difficult to diagnose because there is no specific test for them. Scientists are analyzing the patterns of inflammatory molecules in blood samples from people with the disorders in an effort to find biomarkers that help detect disease or predict outcomes.
- Researchers are working on optimizing visualization techniques, such as ultrasound, PET/CT, MRI, for diagnosing polymyalgia rheumatica and giant cell arteritis.
For More Info
U.S. Food and Drug Administration
Toll free: 888-INFO-FDA (888-463-6332)
Drugs@FDA is a searchable catalog of FDA-approved drug products.
Centers for Disease Control and Prevention, National Center for Health Statistics
American College of Rheumatology
National Organization for Rare Disorders
If you need more information about available resources in your language or other languages, please visit our webpages below or contact the NIAMS Information Clearinghouse at NIAMSInfo@mail.nih.gov.